Eva U. Graefe-Mody

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patients

Tim Heise, Eva U. Graefe-Mody, S. Hüttner et al. · Diabetes Obesity and Metabolism · 2009 · 175 citations

Medicine, Pharmacokinetics, Pharmacology +16

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

S. Hüttner, Eva U. Graefe-Mody, B. Withopf et al. · The Journal of Clinical Pharmacology · 2008 · 133 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects

Akiko Sarashina, Shogo Sesoko, Mitsuyoshi Nakashima et al. · Clinical Therapeutics · 2010 · 59 citations

Medicine, Endocrinology, Pharmacology +13

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

Eva U. Graefe-Mody, Steven J. Padula, Arne Ring et al. · Current Medical Research and Opinion · 2009 · 57 citations

Medicine, Pharmacokinetics, Pharmacology +17

Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients

Yoshiharu Horie, Shigeto Kanada, Hirotaka Watada et al. · Clinical Therapeutics · 2011 · 45 citations

Medicine, Pharmacokinetics, Pharmacology +13